• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Wright Medical Group, Inc. Announces Cost Restructuring Plan

Wright Medical Group, Inc. Announces Cost Restructuring Plan

September 15, 2011 By MassDevice

ARLINGTON, Tenn.–(BUSINESS WIRE)–Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical
device company and a leading provider of surgical solutions for the foot
and ankle market, announced today that it is implementing a cost
restructuring plan to foster growth, enhance profitability and cash
flow, and build shareholder value. Wright Medical expects that the
initial phase of this plan will be completed during the next nine
months, with additional efficiency initiatives to be implemented
throughout 2012 and beyond.

Under the plan, Wright Medical has begun to implement numerous
initiatives to reduce spending, including streamlining select aspects of
its international selling and distribution operations, reducing the size
of its international product portfolio, adjusting plant operations to
align with the Company’s volume and mix expectations and rationalizing
its research and development projects. In total, Wright Medical plans to
reduce its workforce by approximately 80 employees, or 6%. The Company
has notified affected employees and has taken steps to ensure a smooth
transition.

Objectives of the plan include generating annual operating efficiencies
to bolster the Company’s financial results in 2012 and beyond while
enabling investments in longer term strategies for growth. Wright
Medical estimates that the plan will have a favorable impact to adjusted
earnings per share of approximately $0.05 to $0.06 in 2012, and a
favorable annual impact of approximately $0.08 thereafter.

David D. Stevens, Interim Chief Executive Officer stated, “Our industry
continues to face a challenging economic environment and, after
extensive analysis and consideration, we believe this plan will enhance
the Company’s prospects for growth and value creation. We are taking
these actions now to better position the Company to grow its earnings in
2012 and we are confident that this plan will result in a leaner, more
cost efficient operation, which is in the best interest of our business
and all of our stakeholders. Additionally, the Company continues to have
a strong balance sheet and is positioned well for investments in
acquisitions to drive future growth.”

The Company expects to record total pre-tax charges related to the cost
restructuring plan in the range of approximately $25 million to $30
million, of which approximately $6 million to $8 million is expected to
be non-cash. These charges will include, among others, severance and
benefits costs, excess and obsolete inventory charges, asset impairment
charges, external legal and professional fees and contract termination
costs. A majority of these charges are expected to be recorded in the
third and fourth quarters of 2011, with some additional charges to be
recorded during the first half of 2012.

The Company’s adjusted earnings per share excludes costs associated with
the restructuring plan, the transaction costs and non-cash deferred
financing fees associated with the Convertible Notes tendered, possible
future acquisitions, other material future business developments,
non-cash stock-based compensation expense, and costs associated with the
Company’s DPA (including the associated independent monitor).

Cautionary Note Regarding Forward-Looking
Statements

This press release contains “forward-looking statements” as
defined under U.S. federal securities laws. These statements reflect
management’s current knowledge, assumptions, beliefs, estimates, and
expectations and express management’s current views of future
performance, results, and trends and may be identified by their use of
terms such as anticipate, believe, could, estimate, expect, intend, may,
plan, predict, project, will, and other similar terms. Forward-looking
statements are subject to a number of risks and uncertainties that could
cause our actual results to materially differ from those described in
the forward-looking statements.
Readers should not place
undue reliance on forward looking statements. Such statements are made
as of the date of this press release, and we undertake no obligation to
update such statements after this date. Risks and uncertainties that
could cause our actual results to materially differ from those described
in forward-looking statements include those discussed in our filings
with the Securities and Exchange Commission (including those described
in Item 1A of our Annual Report on Form 10-K for the year ended December
31, 2010, and our subsequently filed quarterly reports, under the
heading “Risk Factors” and elsewhere), and the impact of our settlement
of the federal investigation into our consulting arrangements with
orthopaedic surgeons relating to our hip and knee products in the United
States, including our compliance with the Deferred Prosecution Agreement
through September 2011 (which could be extended) and the Corporate
Integrity Agreement through September 2015.
Our failure to
comply with the Deferred Prosecution Agreement or the Corporate
Integrity Agreement could expose us to significant liability including,
but not limited to, extension of the term of the Deferred Prosecution
Agreement, exclusion from federal healthcare program participation,
including Medicaid and Medicare, which would have a material adverse
effect on our financial condition, results of operations and cash flows,
potential prosecution, including under the previously-filed criminal
complaint, civil and criminal fines or penalties, and additional
litigation cost and expense. In addition, a breach of the Deferred
Prosecution Agreement or the Corporate Integrity Agreement could result
in an event of default under the Senior Credit Facility, which in turn
could result in an event of default under the Indenture.

Additional risks and uncertainties that could cause our actual
results to materially differ from those described in forward-looking
statements include the possibility of litigation brought by
shareholders, including private securities litigation and shareholder
derivative suits, which if initiated, could divert management’s
attention, harm our business and/or reputation and result in significant
liabilities; demand for and market acceptance of our new and existing
products; future actions of governmental authorities and other third
parties; tax measures; business development and growth opportunities;
product quality or patient safety issues; products liability claims;
enforcement of our intellectual property rights; the geographic and
product mix impact on our sales; retention of sales representatives and
independent distributors; inventory reductions or fluctuations in buying
patterns by wholesalers or distributors; ability to realize the
anticipated benefits of restructuring initiatives; and impact of the
commercial and credit environment on us and our customers and suppliers.

Wright Medical Group, Inc. is a global orthopaedic medical device
company and a leading provider of surgical solutions for the foot and
ankle market. The Company specializes in the design, manufacture and
marketing of devices and biologic products for extremity, hip and knee
repair and reconstruction. The Company has been in business for more
than 60 years and markets its products in over 60 countries worldwide.
For more information about Wright Medical, visit the Company’s website
at www.wmt.com.

Contacts

Wright Medical Group, Inc.
Lance Berry, 901-867-4607

Filed Under: Orthopedics Tagged With: Layoffs, wrightmedical

In case you missed it

  • Technical Brief – “Understanding the Extensive OEM Benefits of Total Linear Motion Solutions.”
  • Exactech launches total hip arthroplasty system
  • Lensar announces first patients treated with Ally adaptive cataract treatment
  • HeartBeam submits heart attack diagnostic platform for FDA 510(k) clearance
  • GE Healthcare leads AliveCor Series F funding for ECG tech
  • New FDA ruling may lower costs for over-the-counter hearing aids
  • Data supports Sight Sciences’ Omni surgical system for glaucoma
  • Integra founder Richard Caruso has died
  • Moximed raises $40M for implantable shock absorber for knee osteoarthritis
  • Philips names Roy Jakobs as CEO amid ventilator, CPAP recalls
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio
  • Outset Medical wins national VA contract
  • Inspire Medical Systems appoints former Zimmer Biomet exec as VP of investor relations
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year

RSS From Medical Design & Outsourcing

  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy